Table 1.
Baseline characteristics of the study population
| Characteristic | AI user (n = 42) | Non-AI user (n = 43) | p value |
|---|---|---|---|
| Duration of AIs use, mon | 34.3 ± 16.9 | - | - |
| Age at the time of operation, yra | 56.5 (8) | 54.0 (7) | 0.143 |
| Age at the time of ultrasonography, yra | 60.0 (8) | 57.0 (7) | 0.066 |
| Elapsed time to IMT after operation, mona | 33.0 (20) | 30.0 (40) | 0.187 |
| History of DM | 8 (19.0) | 11 (25.6) | 0.470 |
| Duration of DM, yra | 9.8 (11.0) | 6.6 (2.0) | 0.477 |
| History of HTN | 13 (31.0) | 9 (21.4) | 0.457 |
| Use of antiplateletes | 6 (14.3) | 4 (9.5) | 0.736 |
| Use of statin | 20 (60.6) | 24 (70.6) | 0.547 |
| Smoking | 0 | 1 (2.4) | 0.991 |
| TNM stage (≥ 2a) | 22 (52.4) | 18 (41.9) | 0.331 |
| BMI, kg/m2 | 24.1 ± 2.4 | 24.1 ± 2.6 | 0.999 |
| FBS, mg/dLa | 97.5 (16) | 99.0 (15) | 0.812 |
| Total cholesterol, mg/dL | 206.1 ± 42.1 | 216.7 ± 39.5 | 0.233 |
| HDL-C, mg/dL | 53.7 ± 13.4 | 53.4 ± 10.3 | 0.902 |
| Triglycerides, mg/dLa | 123.0 (77) | 129.0 (74) | 0.916 |
| LDL-C, mg/dL | 122.5 ± 37.6 | 129.5 ± 41.0 | 0.415 |
| QUICKIa | 0.35 ± 0.01 | 0.35 ± 0.01 | 0.735 |
| HOMA-IRa | 1.89 (2.12) | 1.75 (1.67) | 0.872 |
| Chemotherapy | 21 (50.0) | 33 (76.7) | 0.010 |
| Radiotherapy | 24 (57.1) | 22 (51.2) | 0.580 |
| Chemotherapy plus radiotherapy | 12 (28.6) | 18 (41.9) | 0.200 |
Values are presented as mean ± SD or number (%).
AI, aromatase inhibitor; IMT, intima-media thickness; DM, diabetes mellitus, HTN, hypertension; TMN, tumor, nodes and metastasis; BMI, body mass index; FBS, fasting blood sugar; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; QUICKI, quantitative insulin-sensitivity check index; HOMA-IR, homeostasis model assessment of insulin resistance.
a
Median (interquartile range) with non-parametric data. Differences between groups of patients were analyzed by the chisquare test, independent t test, and Mann-Whitney U test.